Drugs / TR115
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05650580 | Apr 2023 → Jul 2025 | non-Hodgkin lymphoma | Tarapeutics Science Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07639879 | Jul 2026 → Jul 2029 expected | mature T-cell and NK-cell non-Hodgkin lymphoma | Tarapeutics Science Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TR115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650580 ↗ |
| Action | Inhibit | “TR115, an EZH2 inhibitor” NCT07639879 ↗ |
| Route | Oral | “TR115 tablet will be administered orally” NCT05650580 ↗ |
| Target | EZH2 | “TR115, an EZH2 inhibitor” NCT07639879 ↗ |